Advances in Locally Advanced and Metastatic Kidney Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".
Deadline for manuscript submissions: 4 July 2024 | Viewed by 314
Special Issue Editors
Interests: urologic oncology; kidney cancer; translational research; testicular cancer; upper tract urothelial carcinoma
Special Issue Information
Dear Colleagues,
Our biological understanding and clinical management of kidney cancer has evolved considerably in recent years. In particular, the advent of novel immune checkpoint inhibitors has led to unprecedented responses in metastatic disease, with improvements in survival outcomes for patients. This has paved the way for the emergence of rational, synergistic combinations of immunotherapies and targeted therapies.
Advanced renal cell carcinoma (RCC) exhibits a wide clinical spectrum, ranging from non-metastatic, high-risk or locally advanced tumors, to oligometastatic disease, to more widely disseminated metastatic involvement. In the locally advanced space, increasing interest has turned to administering systemic therapies in the perioperative (neoadjuvant or adjuvant) setting to help reduce recurrence. In the study of oligometastatic disease, new approaches to the locoregional management of metastatic sites, such as stereotactic radiation, have been employed to delay or obviate the need for systemic therapy while minimizing morbidity. In more widely disseminated diseases, novel therapeutic agents and rational combinations continue to emerge for both clear cell and non-clear cell RCC histologies. The role and timing for cytoreductive nephrectomy in metastatic disease continue to evolve, and the ideal setting remains unknown at present. Furthermore, diagnostic, prognostic, and predictive circulating biomarkers continue to remain an active area of research interest across the spectrum of RCC, while diagnostic imaging has also seen advances in both diagnosis and potential theranostic applications.
In this Special Issue, we are seeking high-quality, novel work highlighting advances in locally advanced and metastatic kidney cancer, pertaining to the themes delineated above. We look forward to receiving your contributions.
Dr. Nirmish Singla
Dr. Yasser Ged
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- kidney cancer
- renal cell carcinoma
- locally advanced
- oligometastatic
- metastatic
- novel therapeutics
- diagnostic imaging
- biomarkers
- multimodal treatment
- cytoreductive nephrectomy
